Book contents
- Anemia
- Anemia
- Copyright page
- Contents
- Contributors
- Preface
- Section 1 The Normal Human Red Blood Cell
- Section 2 The Patient with Anemia
- Section 3 Specific Forms of Anemia
- Section 4 Secondary Anemias
- Section 5 Management of Anemia
- Chapter 31 Pharmacologic Therapy of Anemia
- Chapter 32 Splenectomy
- Section 6 Summary
- Index
- References
Chapter 31 - Pharmacologic Therapy of Anemia
from Section 5 - Management of Anemia
Published online by Cambridge University Press: 18 April 2018
Book contents
- Anemia
- Anemia
- Copyright page
- Contents
- Contributors
- Preface
- Section 1 The Normal Human Red Blood Cell
- Section 2 The Patient with Anemia
- Section 3 Specific Forms of Anemia
- Section 4 Secondary Anemias
- Section 5 Management of Anemia
- Chapter 31 Pharmacologic Therapy of Anemia
- Chapter 32 Splenectomy
- Section 6 Summary
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- AnemiaPathophysiology, Diagnosis, and Management, pp. 217 - 222Publisher: Cambridge University PressPrint publication year: 2017
References
Bothwell, TH. Overview and mechanisms of iron regulation. Nutr Rev. 1995; 53:237–245.CrossRefGoogle ScholarPubMed
Teucher, B, Olivares, M, Cori, H. Enhancers of iron absorption: ascorbic acid and other organic acids. Int J Vitam Nutr Res. 2004; 74:403–419.CrossRefGoogle ScholarPubMed
Cancelo-Hidalgo, MJ, Castelo-Branco, C, Palacios, S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013; 29:291–303.CrossRefGoogle ScholarPubMed
Melamed, N, Ben-Haroush, A, Kaplan, B, et al. Iron supplementation in pregnancy—does the preparation matter? Arch Gynecol Obstet. 2007; 276:601–604.Google Scholar
Rimon, E, Kagansky, N, Kagansky, M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005; 118:1142–1147.CrossRefGoogle ScholarPubMed
Auerbach, M, Ballard, H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program. 2010; 2010:338–347.Google Scholar
Chertow, GM, Mason, PD, Vaage-Nilsen, O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21:378–382.Google Scholar
Fernández-Bañares, F, Monzón, H, Forné, M. A short review of malabsorption and anemia. World J Gastroenterol. 2009; 15:4644–4652.CrossRefGoogle Scholar
Gafter-Gvili, A, Rozen-Zvi, B, Vidal, L. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013; 52:18–29.CrossRefGoogle ScholarPubMed
Steensma, DP, Sloan, JA, Dakhil, SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011; 29:97–105.Google Scholar
Henry, DH, Dahl, NV, Auerbach, M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12:231–242.CrossRefGoogle ScholarPubMed
Albaramki, J, Hodson, EM, Craig, JC, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012; 1:CD007857.Google Scholar
Macdougall, IC, Padhi, D, Jang, G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant. 2007; 22 Suppl 4:iv2–iv9.Google Scholar
Palmer, SC, Navaneethan, SD, Craig, JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010; 153:23–33.CrossRefGoogle ScholarPubMed
Kansagara, D, Dyer, E, Englander, H, et al. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med. 2013; 159:746–757.Google Scholar
Cody, J, Daly, C, Campbell, M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005; 3:CD003266.Google Scholar
Lau, JH, Gangji, AS, Rabbat, CG, et al. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. Nephrol Dial Transplant. 2010; 25:4002–4009.CrossRefGoogle ScholarPubMed
Tonia, T, Mettler, A, Robert, N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012; 12:CD003407.Google Scholar
Smith, RE Jr., Aapro, MS, Ludwig, H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008; 26:1040–1050.Google Scholar
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cancer- and Chemotherapy-Induced Anemia (V.2.2014). Available at www.nccn.org/professionals/physician_gls/pdf/anemia.pdf (Accessed December 11, 2013).Google Scholar
Goodnough, LT, Monk, TG, Andriole, GL. Erythropoietin therapy. N Engl J Med. 1997; 27:933–938.CrossRefGoogle Scholar